Follow
JA Ledermann
JA Ledermann
Professor of medical oncology, UCL Cancer Institute
Verified email at ucl.ac.uk
Title
Cited by
Cited by
Year
A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ...
New England Journal of Medicine 365 (26), 2484-2496, 2011
25112011
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
23752016
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
20732012
Ovarian cancer
GC Jayson, EC Kohn, HC Kitchener, JA Ledermann
The Lancet 384 (9951), 1376-1388, 2014
20212014
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ...
International Journal of Gynecologic Cancer 26 (1), 2016
18622016
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
16982014
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
16382017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
15682017
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Icon and Ago Collaborators
The Lancet 361 (9375), 2099-2106, 2003
14142003
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ...
International Journal of Gynecologic Cancer 31 (1), 2021
12952021
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
JA Ledermann, FA Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, ...
Annals of oncology 24, vi24-vi32, 2013
10352013
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ...
Annals of Oncology 30 (5), 672-705, 2019
10272019
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
8802015
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label …
RD James, R Glynne-Jones, HM Meadows, D Cunningham, AS Myint, ...
The lancet oncology 14 (6), 516-524, 2013
7102013
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
MT Seymour, TS Maughan, JA Ledermann, C Topham, R James, ...
The Lancet 370 (9582), 143-152, 2007
7072007
Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial
T Ruers, F Van Coevorden, CJA Punt, JPEN Pierie, I Borel-Rinkes, ...
JNCI: Journal of the National Cancer Institute 109 (9), djx015, 2017
5882017
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre …
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ...
The lancet oncology 19 (3), 295-309, 2018
5542018
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ...
Annals of Oncology 30 (7), 1080-1087, 2019
5422019
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo …
JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 17 (11), 1579-1589, 2016
4872016
Guidelines for resection of colorectal cancer liver metastases
OJ Garden, M Rees, GJ Poston, D Mirza, M Saunders, J Ledermann, ...
Gut 55 (suppl 3), iii1-iii8, 2006
4872006
The system can't perform the operation now. Try again later.
Articles 1–20